iBio, Inc. Announces Stockholder Meeting for Reverse Stock Split
Ticker: IBIO · Form: 8-K · Filed: 2024-11-25T00:00:00.000Z
Sentiment: neutral
Topics: reverse-split, stockholder-meeting, corporate-action
Related Tickers: IBIO
TL;DR
IBIO calling shareholder meeting Dec 20 to vote on reverse stock split. Big changes coming.
AI Summary
On November 21, 2024, iBio, Inc. filed an 8-K report detailing its financial results and announcing a special meeting of stockholders. The meeting, scheduled for December 20, 2024, will address proposals including the approval of a reverse stock split and amendments to the company's certificate of incorporation.
Why It Matters
The company is seeking shareholder approval for a reverse stock split, which could significantly alter the stock's per-share price and potentially impact its marketability and listing status.
Risk Assessment
Risk Level: medium — Reverse stock splits can be a sign of financial distress or an attempt to meet exchange listing requirements, carrying inherent risks for investors.
Key Numbers
- 001-35023 — Commission File Number (Identifies the company's SEC filing history.)
- 26-2797813 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- iBio, Inc. (company) — Registrant
- November 21, 2024 (date) — Date of Report
- December 20, 2024 (date) — Stockholder Meeting Date
- Delaware (jurisdiction) — State of Incorporation
- San Diego, California (location) — Principal Executive Offices
FAQ
What is the primary purpose of the special meeting of stockholders?
The primary purpose is to vote on proposals including the approval of a reverse stock split and amendments to the company's certificate of incorporation.
When is the special meeting of stockholders scheduled to take place?
The special meeting is scheduled for December 20, 2024.
What specific proposals will be voted on at the meeting?
Shareholders will vote on proposals including the approval of a reverse stock split and amendments to the company's certificate of incorporation.
What is the company's state of incorporation?
iBio, Inc. is incorporated in Delaware.
Where are iBio, Inc.'s principal executive offices located?
The principal executive offices are located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.
From the Filing
0001104659-24-122387.txt : 20241125 0001104659-24-122387.hdr.sgml : 20241125 20241125083010 ACCESSION NUMBER: 0001104659-24-122387 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20241121 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241125 DATE AS OF CHANGE: 20241125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 241492084 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 tm2429233d1_8k.htm FORM 8-K false 0001420720 0001420720 2024-11-21 2024-11-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (date of earliest event reported): November 21, 2024   iBio, Inc. (Exact name of registrant as specified in charter)   Delaware (State or other jurisdiction of incorporation)   001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.)   11750 Sorrento Valley Road , Suite 200 San Diego , California 92121 (Address of principal executive offices and zip code)   ( 979 ) 446-0027 (Registrant’s telephone number including area code)   N/A (Former Name and Former Address)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:     ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)     ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share IBIO NYSE American   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company   ¨   If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨             Item 2.02. Results of Operations and Financial Condition.   On November 25, 2024, iBio, Inc. (the “Company”) issued a press release announcing the appointment of two new independent directors. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.   The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Cur